DDInter624 DDInter1676
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatitis
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease)
Efavirenz (Compound) binds CYP2C19 (Gene)
Efavirenz (Compound) upregulates IKBKB (Gene)
Efavirenz (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class)
Efavirenz (Compound) downregulates POLR2I (Gene)
Efavirenz (Compound) causes Hepatitis (Side Effect)